Abstract
Su1863 – Comparative Efficacy of Vedolizumab and Adalimumab As Second Line Therapy in Ulcerative Colitis Patients Previously Treated with Infliximab
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
